Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
Merck & Co., Inc. remains the largest U.S. pharma company in 2025, driven by oncology and Keytruda, despite looming patent expiration risks. Keytruda accounts for over half of MRK's ...
Merck topped first-quarter sales estimates as Winrevair and injectable Keytruda Qlex helped support revenue growth.
Hosted on MSN
Merck's Keytruda: A lifesaving drug, a global divide
A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of the world's best selling drugs while leaving many patients struggling to ...
Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results